0.0010USD0.00%Mkt Cap: 4854 USDP/E: —Last update: 2026-05-25
Panbela Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of disruptive therapeutics for the treatment of patients with urgent unmet medical needs. The company's lead product cand…
Industry Peers
Biotechnology110.61BUSDP/E 25.8
106.49BDKKP/E 20.5
66.47BUSDP/E 15.5
46.51BEURP/E 30.5
43.17BEURP/E 35.9
39.41BUSDP/E 74.0
32.84BUSD—
31.18BSEKP/E 46.1
Indicators:|
Key Statistics
Company
Market Cap4.85K USD
Enterprise Value1.67M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-25.26M USD
Revenue/Share—
Last Price0.0010 USD
Fiscal Year EndDec 2023
MR QuarterSep 2024
Employees7
CountryUS
SectorHealthcare
IndustryBiotechnology
ISINUS69833W2061
Valuation
P/E (Trailing)—
P/E (Forward)-0.00
PEG—
EV/EBITDA—
EV/Revenue—
P/S—
P/B-0.00
EPS (TTM)-34.51
EPS (Forward)-5.66
52W Range
0.00010% of range2.500
52W High2.500 USD
52W Low0.0001 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE536.37%
ROA-214.06%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-25.25M USD
CapEx (TTM)—
FCF Margin—
FCF Yield-164400.49%
Net Debt1.67M USD
Net Debt/EBITDA—
Balance Sheet
Debt/Equity-1.10
Current Ratio0.26
Quick Ratio0.25
Book Value/Sh-3.7420 USD
Cash/Share0.9740 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay DateNov 8, 2017
Splits
Last Split1:20
Split DateJan 18, 2024
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.4.85M
Float4.85M
Insiders0.00%
Institutions0.00%
Short Interest
Short Ratio0.1d
Short % Float3.07%
Short % Out.3.07%
Shares Short106.97K
Short (prev mo.)46.36K
Technical
SMA 500.0031 (-68.1%)
SMA 2000.0243 (-95.9%)
Beta43.80
S&P 52W Chg28.31%
Avg Vol (30d)1.99K
Avg Vol (10d)259
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—